Singapore: Crystal Pharmatech is going to open its laboratories in China in order to provide customized, materials science development service packages in drug R&D.

Crystal has adopted a collaborative business model between its customers and contract manufacturing organizations (CMO) and this has led to the steady growth in revenues since the firm was founded in 2010. The crystal team comprises of pharmaceutical specialists, whose former experience at top drug makers includes development of 200 new chemical entities (NCE's) and inventorship on 40 polymorph patents.

According to Dr Alex Chen, founder and CEO of Crystal Pharmatech, "We act as the materials research conduit for virtual and small to mid-size drug companies to determine the optimal path for delivering their compounds to animal tox studies or first in humans (FIH). Our unique matrix system minimizes kills due to formulatability, and provides fundamental material property evaluation of compounds for our customers."

In a relatively short time, Crystal Pharmatech has gained respect in the pharmaceutical industry as a preferred provider based on its founding principles and a skill set similar to one of the top five pharmaceutical companies.

"Collaboration encourages better monitoring of material property issues that hamper progress and planning in formulation development," explained Dr Ann Newman, Crystal Pharmatech's vice president scientific development. "We help our clients connect the dots between from selection, API and formulation manufacturing, and clinical supplies." added Dr Newman.